Less than a year after its founding, US-based Metsera has filed for an initial public offering to accelerate the development of a its long-acting injectable GLP-1 agonist.
发布者：BY ALBERT RONNING-ANDERSSON，转转请注明出处：https://robotalks.cn/new-york-based-obesity-biotech-startup-files-for-ipo-in-the-us/
The renewed business brand name identification leans right into the business’s heritage of linking individuals, details and concepts to open unknown opportunities.
Robot safety start-up Unflinching, which utilizes a quadruped robotic (primary photo) as component of its safety remedy, has actually formally released after pre-seed financing fro…
DANX has relocated its Stockholm distribution hub to a new, larger facility to reduce goods’ handling times, increase the volume of cargo it handles, and meet the demands of its su…
Billing rate stays a substantial obstacle to conquer in the mass market fostering of traveler and industrial electrical automobiles (EVs). According to professionals, quick billing…
Computer system Vision can be made use of to boost procedure adherence in the storage facility Flymingo is an Israeli computer system vision business that determines supply chain b…
